Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ultragenyx Pharmaceutical Inc.

NASDAQ: RARE · Life Sciences · 7 alerts · CIK 1515673

Ultragenyx Pharmaceutical Inc. stories on ALFA USA NewsRead the news →
Share price
$16.70Close, Nov 17
Market cap
$1.7B
Shares outstanding
101.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ultragenyx Pharmaceutical Inc. filings on SEC EDGAR ↗

9:01 AM ET 8-K
Divestiture

Ultragenyx Pharmaceutical Divestiture for $203M

Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.

Value
$203M
9:00 AM ET 8-K
Divestiture

Ultragenyx Pharmaceutical Divestiture for $210M

Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. The PRV was recently awarded by the FDA following the approval of GENGLYCOS for the treatment of glycogen storage disease type Ia. Under a prior agreement, the company will pay 20% of the gross proceeds from this sale to the NIH.

Value
$210M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.